Timing and Duration of Acute Hepatitis C Treatment
Hepatitis C
About this trial
This is an interventional treatment trial for Hepatitis C focused on measuring Clinical trial, Randomized, Treatment, Prospective, Parallel Assignment, Efficacy Safety Study
Eligibility Criteria
Inclusion Criteria: Age: 18-50 years, with or without symptoms Diagnosis of acute hepatitis C: elevated serum alanine aminotransferase (ALT) > 10 times the upper limit of normal (ULN) Seroconversion from negative to positive anti-HCV antibody status (third-generation enzyme-linked immunosorbent assay) Conversion from negative to positive polymerase chain reaction (PCR) for HCV-RNA, ruling out other causes of hepatitis by history and appropriate serologic and virologic studies. Exclusion Criteria: Decompensated liver disease Coinfection with human immunodeficiency virus (HIV) or Schistosoma mansoni Marked anemia (hemoglobin level ≤ 120 g/L in women and ≤ 130 g/L in men) Neutropenia (< 1,500/mm3) Thrombocytopenia (< 90,000/mm3) A creatinine concentration > 1.5 times ULN Serum alpha-fetoprotein > 25 ng/ml An organ transplant Neoplastic disease Severe cardiac or pulmonary disease Unstable thyroid dysfunction A psychiatric disorder Seizure disorder Severe retinopathy A current pregnancy or were breast feeding or unwillingness to practice contraception Therapy with immunomodulatory agents within the last 6 months Alcohol or drug dependence within 1 year of study entry.
Sites / Locations
- ASU
- ASU Specialized Hospital
- Shebin Liver Center